Systemic treatment for alopecia areata

These medicines reach the body through tablets or another non-local route and alter immune activity. The decision requires an individual balance between likely benefit, treatment burden, health history, infection risk, monitoring needs, and the possibility of hair loss returning after therapy changes.

JAK inhibitors interrupt selected signalling pathways involved in the follicle-directed immune response. Oral corticosteroids suppress inflammation more broadly and may be used in selected circumstances, often with careful limits because they can affect many body systems.

Eligibility is not determined by patch count alone. The pace and distribution of loss, brow or lash involvement, previous treatment, age, other conditions, current medicines, pregnancy considerations, and personal goals shape the discussion. Approval and suitable options can also vary by medicine and patient.

Give the prescriber a complete history of infections, vaccinations, clotting problems, heart or liver concerns, pregnancy plans, and every medicine or supplement you use. Screening and blood tests may be needed before treatment and at intervals afterward, depending on the chosen drug.

Take the medicine exactly as directed and attend monitoring visits even if you feel well. Do not share doses, double a missed dose, or combine immune-modifying treatments without approval. Keep a simple photographic record so that regrowth, spread, and any new pattern can be compared over time.

Contact the prescribing team promptly for fever, a persistent cough, painful rash, signs of infection, unusual bruising, or other symptoms listed in your medicine instructions. Sudden chest pain, severe breathlessness, one-sided leg swelling, or a severe allergic reaction needs emergency care.

Tell the team before surgery, vaccination, pregnancy, or starting another prescription. If side effects develop, seek advice rather than stopping abruptly unless emergency instructions tell you to do so, because the appropriate response depends on the medicine and symptom.

Ask why a systemic option is being proposed, what screening and ongoing tests it requires, which infections or other adverse effects need prompt reporting, how response will be assessed, and what the plan is if treatment is ineffective, interrupted, or discontinued.